EGFR and non-small cell lung carcinoma: For patients suffering from non-small cell lung cancer, despite the fact that EGFR–tyrosine kinase inhibitors (EGFR-TKI) can be employed for treatment, the emergence of drug resistance significantly influences survival and prognosis.